[Primary study of the recombinant immunotoxin DT390-mRantes in EAE therapy].
OBJECTIVE
To construct a novel eukaryotic expression plasmid including the recombinant immunotoxin DT390-mRantes and treat experimental autoimmune encephalomyelitis (EAE) in mice.


METHODS
EAE in C57BL/6 mice were induced by the extracted MBP. The mRantes fragment was inserted into the eukaryotic expression plasmid SRalpha containing DT390. Then cationic liposome-embedded plasmid DNA was injected into the muscles of the hind-limbs in mice. The effect of DT390-mRantes was evaluated by observing clinical symptoms, pathological changes of brain, relative cytokine of peripheral blood, and the proportion of T cells and B cells.


RESULTS
The recombinant immunotoxin DT390-mRantes was successfully constructed. Compared the mice in treated group with those in untreated group the clinical symptoms of EAE were alleviated, the infiltration of inflammatory cells were decreased, the IFN-gamma level was fallen, and the ratio of T/B cells was decreased.


CONCLUSIONS
The recombinant immunotoxin DT390-mRantes has distinct effects on EAE in mice, which may be used for beneficial reference to the therapy of MS.
Jia
Yi
Y
Department of Material Evidence School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, China. yijia781021@tom.com
Li
Hong
H
Chen
Wen-Jie
WJ
Lu
Mei-Li
ML
Li
Ming-Yuan
MY
Jiang
Zhong-Hua
ZH
Zhang
Lin
L
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism; D018946:Chemokine CCL5 / Q000235:genetics*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D005260:Female; D005434:Flow Cytometry; D007150:Immunohistochemistry; D016233:Immunotherapy, Active / Q000379:methods*; D000922:Immunotoxins / Q000235:genetics / Q000627:therapeutic use; D007371:Interferon-gamma / Q000378:metabolism; D008081:Liposomes / Q000737:chemistry; D051379:Mice; D008810:Mice, Inbred C57BL; D010957:Plasmids / Q000235:genetics / Q000276:immunology; D011897:Random Allocation; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism
D018946:Chemokine CCL5; D000922:Immunotoxins; D008081:Liposomes; D011994:Recombinant Proteins; D007371:Interferon-gamma